Yu XL, Zhang HJ, Ren SD et al. Coron Artery Dis 2011;22:87–91.
In this study, the authors demonstrated that early, high-dose loading of atorvastatin before percutaneous coronary intervention in patients with non-ST-segment elevation ACS reduced the risk of periprocedural myocardial injury and levels of periprocedural inflammatory markers. These results suggest that inflammation may play a pathogenic role in periprocedural adverse cardiovascular events.
Beyond their lipid-lowering properties, statins are known to have pleotropic effects including anti-inflammatory properties. In this study, the authors examined whether early administration of a high-dose statin reduced the 30-day incidence of major adverse cardiac events. This was a study of 81 statin-naïve patients with non-ST-segment elevation ACS who were randomized to atorvastatin 80 mg at least 12 h before percutaneous coronary intervention (PCI) with a further 40 mg pre-procedural dose, or placebo. All patients underwent PCI within 4 days of admission. Among them, 33% had non-ST-segment elevation myocardial infarction (NSTEMI), with the remainder presenting with unstable angina.